{"links": [{"source": 0, "target": "t314", "value": "None"}, {"source": 0, "target": "t306", "value": "None"}, {"source": 0, "target": "t290", "value": "None"}, {"source": 0, "target": "t300", "value": "None"}, {"source": "t314", "target": "t315", "value": "None"}, {"source": "t306", "target": "t307", "value": "None"}, {"source": "t306", "target": "t313", "value": "None"}, {"source": "t290", "target": "t291", "value": "None"}, {"source": "t300", "target": "t301", "value": "None"}, {"source": "t315", "target": "t316", "value": "None"}, {"source": "t307", "target": "t308", "value": "None"}, {"source": "t291", "target": "t292", "value": "None"}, {"source": "t301", "target": "t302", "value": "None"}, {"source": "t316", "target": "t317", "value": "None"}, {"source": "t316", "target": "t318", "value": "None"}, {"source": "t316", "target": "t319", "value": "None"}, {"source": "t316", "target": "t320", "value": "None"}, {"source": "t308", "target": "t309", "value": "None"}, {"source": "t292", "target": "t293", "value": "None"}, {"source": "t302", "target": "t305", "value": "None"}, {"source": "t302", "target": "t303", "value": "None"}, {"source": "t318", "target": "d410", "value": "None"}, {"source": "t318", "target": "d118", "value": "None"}, {"source": "t318", "target": "d333", "value": "None"}, {"source": "t319", "target": "d333", "value": "None"}, {"source": "t320", "target": "d169", "value": "None"}, {"source": "t320", "target": "d149", "value": "None"}, {"source": "t320", "target": "d324", "value": "None"}, {"source": "t320", "target": "d155", "value": "None"}, {"source": "t320", "target": "d410", "value": "None"}, {"source": "t309", "target": "t310", "value": "None"}, {"source": "t293", "target": "t294", "value": "None"}, {"source": "t303", "target": "t304", "value": "None"}, {"source": "t310", "target": "t311", "value": "None"}, {"source": "t294", "target": "t295", "value": "None"}, {"source": "t311", "target": "t312", "value": "None"}, {"source": "t295", "target": "t297", "value": "None"}, {"source": "t295", "target": "t296", "value": "None"}, {"source": "t297", "target": "t298", "value": "None"}, {"source": "t296", "target": "t298", "value": "None"}, {"source": "t298", "target": "t299", "value": "None"}], "nodes": [{"category": "disease", "id": 0, "name": "Blood_and_immune_system_conditions_general_and_other", "x": "250", "y": "350", "fixed": "true", "draggable": "true", "value": {"name": "Blood_and_immune_system_conditions_general_and_other"}}, {"category": "treatment", "id": "t314", "name": "newborn baby with jaundice", "draggable": "true", "value": {"name": "newborn baby with jaundice", "type": "treatment related", "time": "", "intention": "", "description": "title:newborn baby with jaundice", "drug": {}}}, {"category": "treatment", "id": "t306", "name": "newborn baby with jaundice", "draggable": "true", "value": {"name": "newborn baby with jaundice", "type": "treatment related", "time": "", "intention": "", "description": "title:newborn baby with jaundice", "drug": {}}}, {"category": "treatment", "id": "t290", "name": "newborn baby being checked for jaundice", "draggable": "true", "value": {"name": "newborn baby being checked for jaundice", "type": "treatment related", "time": "", "intention": "", "description": "title:newborn baby being checked for jaundice", "drug": {}}}, {"category": "treatment", "id": "t300", "name": "baby with obvious or suspected jaundice", "draggable": "true", "value": {"name": "baby with obvious or suspected jaundice", "type": "treatment related", "time": "", "intention": "", "description": "title:baby with obvious or suspected jaundice", "drug": {}}}, {"category": "treatment", "id": "t315", "name": "information and support", "draggable": "true", "value": {"name": "information and support", "type": "information and support", "time": "", "intention": "", "description": "title:information and supporthead:Information and supportOffer parents or carers information about treatment for hyperbilirubinaemia, including:  anticipated duration of treatment reassurance that breastfeeding, nappy-changing and cuddles can usually continue.Encourage mothers of breastfed babies with jaundice to breastfeed frequently, and to wake the baby for feeds if necessary.Provide lactation/feeding support to breastfeeding mothers whose baby is visibly jaundiced.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t307", "name": "information and support", "draggable": "true", "value": {"name": "information and support", "type": "information and support", "time": "", "intention": "", "description": "title:information and supporthead:Information and supportOffer parents or carers verbal and written information on phototherapy including all of the following: why phototherapy is being considered why phototherapy may be needed to treat significant hyperbilirubinaemia  the possible adverse effects of phototherapy the need for eye protection and routine eye care reassurance that short breaks for feeding, nappy changing and cuddles will be encouraged what might happen if phototherapy fails rebound jaundice potential long-term adverse effects of phototherapy potential impact on breastfeeding and how to minimise this.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t313", "name": "phototherapy equipment", "draggable": "true", "value": {"name": "phototherapy equipment", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:phototherapy equipmenthead:Phototherapy equipmentEnsure all phototherapy equipment is maintained and used according to the manufacturers  guidelines.Use incubators or bassinets according to clinical need and availability.Do not use white curtains routinely with phototherapy as they may impair observation of the baby.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t291", "name": "visual inspection", "draggable": "true", "value": {"name": "visual inspection", "type": "treatment related", "time": "", "intention": "", "description": "title:visual inspectionhead:Visual inspectionParents, carers and healthcare professionals should all look for jaundice (visual inspection) in babies.When looking for jaundice (visual inspection):  check the naked baby in bright and preferably natural light examine the sclerae and gums, and press lightly on the skin to check for signs of jaundice in  blanched  skin.Ensure babies with factors associated with an increased likelihood of developing significant hyperbilirubinaemia receive an additional visual inspection by a healthcare professional during the first 48 hours of life.Do not rely on visual inspection alone to estimate the bilirubin level in a baby with suspected jaundice.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t301", "name": "information and support", "draggable": "true", "value": {"name": "information and support", "type": "treatment related", "time": "", "intention": "", "description": "title:information and supporthead:Information and supportOffer parents or carers information about neonatal jaundice that is tailored to their needs and expressed concerns. This information should be provided through verbal discussion backed up by written information. Care should be taken to avoid causing unnecessary anxiety to parents or carers. Information should include: factors that influence the development of significant hyperbilirubinaemia  how to check the baby for jaundice what to do if they suspect jaundice the importance of recognising jaundice in the first 24 hours and of seeking urgent medical advice  the importance of checking the baby s nappies for dark urine or pale chalky stools the fact that neonatal jaundice is common, and reassurance that it is usually transient and harmless reassurance that breastfeeding can usually continue.Ensure that adequate support is offered to all women who intend to breastfeed exclusively. See the NICE pathway on postnatal care for information on breastfeeding support. NICE has written information for the public explaining its guidance on jaundice in newborn babies under 28 days.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Jaundice in newborn babies under 28 days quality standard1Information for parents or carersSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t316", "name": "determining treatment", "draggable": "true", "value": {"name": "determining treatment", "type": "treatment related", "time": "", "intention": "", "description": "title:determining treatmenthead:Determining treatmentUse the bilirubin level to determine the management of hyperbilirubinaemia in all babies (see threshold table and the treatment threshold graphs from the CG98 full guideline).Follow expert advice about care for babies with a conjugated bilirubin level greater than 25 micromol/litre because this may indicate serious liver disease.Do not use the albumin/bilirubin ratio when making decisions about the management of hyperbilirubinaemia.Do not subtract conjugated bilirubin from total serum bilirubin when making decisions about the management of hyperbilirubinaemia (see management thresholds in the threshold table and the treatment threshold graphs from the CG98 full guideline).subhead:Baby under 24 hours old with suspected or obvious jaundiceMeasure and record the serum bilirubin level urgently (within 2 hours).Arrange a referral to ensure that an urgent medical review is conducted (as soon as possible and within 6 hours) to exclude pathological causes of jaundice.Interpret bilirubin levels according to the baby s postnatal age in hours and manage hyperbilirubinaemia according to the threshold table and the treatment threshold graphs from the CG98 full guideline.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Jaundice in newborn babies under 28 days quality standard3Management of hyperbilirubinaemia: treatment thresholdsSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t308", "name": "determining need for phototherapy", "draggable": "true", "value": {"name": "determining need for phototherapy", "type": "treatment related", "time": "", "intention": "", "description": "title:determining need for phototherapyhead:Determining need for phototherapyIn babies who are clinically well, have a gestational age of 38 weeks or more and are more than 24 hours old, and who have a bilirubin level that is below the phototherapy threshold but within 50 micromol/litre of the threshold (see the threshold table and the treatment threshold graphs from the CG98 full guideline), repeat bilirubin measurement as follows: within 18 hours for babies with risk factors for neonatal jaundice (those with a sibling who had neonatal jaundice that needed phototherapy or a mother who intends to exclusively breastfeed) within 24 hours for babies without risk factors.In babies who are clinically well, have a gestational age of 38 weeks or more and are more than 24 hours old, and have a bilirubin level that is below the phototherapy threshold by more than 50 micromol/litre (see the threshold table and the treatment threshold graphs from the CG98 full guideline), do not routinely repeat bilirubin measurement.Do not use phototherapy in babies whose bilirubin does not exceed the phototherapy threshold levels in the threshold table and the treatment threshold graphs from the CG98 full guideline.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t292", "name": "checks after birth", "draggable": "true", "value": {"name": "checks after birth", "type": "treatment related", "time": "", "intention": "", "description": "title:checks after birthhead:Checks after birthIn all babies:  check whether there are factors associated with an increased likelihood of developing significant hyperbilirubinaemia soon after birth  examine the baby for jaundice at every opportunity especially in the first 72 hours.Do not use any of the following to predict significant hyperbilirubinaemia: umbilical cord blood bilirubin level ETCOc measurement umbilical cord blood DAT.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t302", "name": "risk factors", "draggable": "true", "value": {"name": "risk factors", "type": "treatment related", "time": "", "intention": "", "description": "title:risk factorshead:Risk factorsIdentify babies as being more likely to develop significant hyperbilirubinaemia if they have any of the following factors: gestational age under 38 weeks a previous sibling with neonatal jaundice requiring phototherapy mother s intention to breastfeed exclusively visible jaundice in the first 24 hours of life.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t317", "name": "phototherapy", "draggable": "true", "value": {"name": "phototherapy", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:phototherapy", "drug": {}}}, {"category": "treatment", "id": "t318", "name": "exchange transfusion", "draggable": "true", "value": {"name": "exchange transfusion", "type": "treatment related", "time": "", "intention": "albumin\nit is used to treat or prevent low blood volume.\nit is used to treat low blood pressure.\nit is used to replace albumin in people with low blood albumin levels.\nit is used to add back fluid after fluid loss.\nit is used to treat shock.", "description": "title:exchange transfusionhead:Exchange transfusionOffer parents or carers information on exchange transfusion including: the fact that exchange transfusion requires that the baby be admitted to an intensive care bed why an exchange transfusion is being considered why an exchange transfusion may be needed to treat significant hyperbilirubinaemia  the possible adverse effects of exchange transfusions when it will be possible for parents or carers to see and hold the baby after the exchange transfusion.Use a double-volume exchange transfusion to treat babies: whose serum bilirubin level indicates its necessity (see threshold table and the treatment threshold graphs from the CG98 full guideline) and/or with clinical features and signs of acute bilirubin encephalopathy.During exchange transfusion do not: stop continuous intensified phototherapy perform a single-volume exchange use albumin priming routinely administer intravenous calcium.Following exchange transfusion:  maintain continuous intensified phototherapy  measure serum bilirubin level within 2 hours and manage according to the threshold table and the treatment threshold graphs from the CG98 full guideline.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {"calcium": "DB00884", "hold": "DB00748"}}}, {"category": "treatment", "id": "t319", "name": "intravenous immunoglobulin", "draggable": "true", "value": {"name": "intravenous immunoglobulin", "type": "treatment related", "time": "", "intention": "hold\nit is used to relieve coughing.\nif you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for", "description": "title:intravenous immunoglobulinhead:Intravenous immunoglobulinOffer parents or carers information on IVIG including: why IVIG is being considered why IVIG may be needed to treat significant hyperbilirubinaemia the possible adverse effects of IVIG when it will be possible for parents or carers to see and hold the baby.Use IVIG (500 mg/kg over 4 hours) as an adjunct to continuous intensified phototherapy in cases of rhesus haemolytic disease or ABO haemolytic disease when the serum bilirubin continues to rise by more than 8.5 micromol/litre per hour.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {"hold": "DB00748"}}}, {"category": "treatment", "id": "t320", "name": "therapies that should not be used", "draggable": "true", "value": {"name": "therapies that should not be used", "type": "treatment related", "time": "", "intention": "albumin\nit is used to treat or prevent low blood volume.\nit is used to treat low blood pressure.\nit is used to replace albumin in people with low blood albumin levels.\nit is used to add back fluid after fluid loss.\nit is used to treat shock.", "description": "title:therapies that should not be usedhead:Therapies that should not be usedDo not use any of the following to treat hyperbilirubinaemia: agar albumin barbiturates charcoal cholestyramine clofibrate D-penicillamine glycerin manna metalloporphyrins riboflavin traditional Chinese medicine acupuncture homeopathy.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {"clofibrate": "DB00636", "charcoal": "DB09278", "glycerin": "DB09462", "cholestyramine": "DB01432"}}}, {"category": "treatment", "id": "t309", "name": "care and monitoring of baby", "draggable": "true", "value": {"name": "care and monitoring of baby", "type": "treatment related", "time": "", "intention": "", "description": "title:care and monitoring of babyhead:Care and monitoring of babyDuring phototherapy: place the baby in a supine position unless other clinical conditions prevent this ensure treatment is applied to the maximum area of skin  monitor the baby s temperature and ensure the baby is kept in an environment that will minimise energy expenditure (thermoneutral environment)  monitor hydration by daily weighing of the baby and assessing wet nappies support parents and carers and encourage them to interact with the baby.Give the baby eye protection and routine eye care during phototherapy.Use tinted headboxes as an alternative to eye protection in babies with a gestational age of 37 weeks or more undergoing phototherapy.During phototherapy: using clinical judgement, encourage short breaks (of up to 30 minutes) for breastfeeding, nappy changing and cuddles continue lactation/feeding supportdo not give additional fluids to babies who are breastfed. Maternal expressed milk is the additional feed of choice if available, and when additional feeds are indicated.During intensified phototherapy: do not interrupt phototherapy for feeding but continue administering intravenous/enteral feeds continue lactation/feeding support so that breastfeeding can start again when treatment stopsMaternal expressed milk is the additional feed of choice if available, and when additional feeds are indicated.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t293", "name": "baby with suspected or obvious jaundice", "draggable": "true", "value": {"name": "baby with suspected or obvious jaundice", "type": "treatment related", "time": "", "intention": "", "description": "title:baby with suspected or obvious jaundice", "drug": {}}}, {"category": "treatment", "id": "t305", "name": "care of baby with prolonged jaundice", "draggable": "true", "value": {"name": "care of baby with prolonged jaundice", "type": "treatment related", "time": "", "intention": "", "description": "title:care of baby with prolonged jaundicehead:Care of baby with prolonged jaundiceIn babies with a gestational age of 37 weeks or more with jaundice lasting more than 14 days, and in babies with a gestational age of less than 37 weeks and jaundice lasting more than 21 days:  Look for pale chalky stools and/or dark urine that stains the nappy. Measure the conjugated bilirubin. Carry out a full blood count. Carry out a blood group determination (mother and baby) and DAT. Interpret the result taking account of the strength of reaction, and whether mother received prophylactic anti-D immunoglobulin during pregnancy. Carry out a urine culture. Ensure that routine metabolic screening (including screening for congenital hypothyroidism) has been performed.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t303", "name": "assessment", "draggable": "true", "value": {"name": "assessment", "type": "treatment related", "time": "", "intention": "", "description": "title:assessment", "drug": {}}}, {"category": "treatment", "id": "t310", "name": "treatment levels", "draggable": "true", "value": {"name": "treatment levels", "type": "treatment related", "time": "", "intention": "", "description": "title:treatment levelshead:Treatment levelsUse phototherapy to treat significant hyperbilirubinaemia (see the threshold table and the treatment threshold graphs  from the CG98 full guideline) in babies.Consider intensified phototherapy to treat significant hyperbilirubinaemia in babies if any of the following apply: the serum bilirubin level is rising rapidly (more than 8.5 micromol/litre per hour) the serum bilirubin is at a level within 50 micromol/litre below the threshold for which exchange transfusion is indicated after 72 hours or more since birth (see threshold table and the treatment threshold graphs from the CG98 full guideline). the bilirubin level fails to respond to initial phototherapy (that is, the level of serum bilirubin continues to rise, or does not fall, within 6 hours of starting phototherapy). If the serum bilirubin level falls during intensified phototherapy to a level 50 micromol/litre below the threshold for which exchange transfusion is indicated reduce the intensity of phototherapy. Do not use sunlight as treatment for hyperbilirubinaemia.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t294", "name": "bilirubin level measurement", "draggable": "true", "value": {"name": "bilirubin level measurement", "type": "treatment related", "time": "", "intention": "", "description": "title:bilirubin level measurementhead:Bilirubin level measurementUse serum bilirubin measurement for babies: in the first 24 hours of life or who have a gestational age of less than 35 weeks.In babies who have a gestational age of 35 weeks or more, and who are over 24 hours old: use a transcutatneous bilirubinometer to measure the bilirubin level if a transcutaneous bilirubinometer is not available, measure the serum bilirubin if a transcutaneous bilirubinometer measurement indicates a bilirubin level greater than 250 micromol/litre, measure the serum bilirubin to check the result use serum bilirubin measurement if bilirubin levels are at or above the relevant treatment thresholds for their age, and for all subsequent measurements.Do not use an icterometer to measure bilirubin levels in babies.Do not measure bilirubin levels routinely in babies who are not visibly jaundiced.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Jaundice in newborn babies under 28 days quality standard2Measurement of bilirubin level in babies more than 24\u00a0hours oldSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t304", "name": "treatment", "draggable": "true", "value": {"name": "treatment", "type": "treatment related", "time": "", "intention": "", "description": "title:treatment", "drug": {}}}, {"category": "treatment", "id": "t311", "name": "monitoring bilirubin levels during therapy", "draggable": "true", "value": {"name": "monitoring bilirubin levels during therapy", "type": "treatment related", "time": "", "intention": "", "description": "title:monitoring bilirubin levels during therapyhead:Monitoring bilirubin levels during therapyDuring phototherapy: repeat serum bilirubin measurement 4\u20136 hours after initiating phototherapy repeat serum bilirubin measurement every 6\u201312 hours when the serum bilirubin level is stable or falling.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t295", "name": "risk factors for kernicterus", "draggable": "true", "value": {"name": "risk factors for kernicterus", "type": "treatment related", "time": "", "intention": "", "description": "title:risk factors for kernicterushead:Risk factors for kernicterusIdentify babies with hyperbilirubinaemia as being at increased risk of developing kernicterus if they have any of the following: a serum bilirubin level greater than 340 micromol/litre in babies with a gestational age of 37 weeks or more a rapidly rising bilirubin level of greater than 8.5 micromol/litre per hour  clinical features of acute bilirubin encephalopathy.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t312", "name": "stopping phototherapy", "draggable": "true", "value": {"name": "stopping phototherapy", "type": "treatment related", "time": "", "intention": "", "description": "title:stopping phototherapyhead:Stopping phototherapyStop phototherapy once serum bilirubin has fallen to a level at least 50 micromol/litre below the phototherapy threshold (see threshold table and the treatment threshold graphs  from the CG98 full guideline).Check for rebound of significant hyperbilirubinaemia with a repeat serum bilirubin measurement 12\u201318 hours after stopping phototherapy. Babies do not necessarily have to remain in hospital for this to be done.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t297", "name": "baby over 24 hours", "draggable": "true", "value": {"name": "baby over 24 hours", "type": "treatment related", "time": "", "intention": "", "description": "title:baby over 24 hourshead:Baby over 24 hours old with suspected or obvious jaundiceMeasure and record the bilirubin level urgently (within 6 hours).SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t296", "name": "baby under 24 hours", "draggable": "true", "value": {"name": "baby under 24 hours", "type": "treatment related", "time": "", "intention": "", "description": "title:baby under 24 hourshead:Baby under 24 hours old with suspected or obvious jaundiceMeasure and record the serum bilirubin level urgently (within 2 hours).Continue to measure the serum bilirubin level every 6 hours until the level is both: below the treatment threshold stable and/or falling.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t298", "name": "assessment for underlying disease", "draggable": "true", "value": {"name": "assessment for underlying disease", "type": "treatment related", "time": "", "intention": "", "description": "title:assessment for underlying diseasehead:Assessment for underlying diseaseIn addition to a full clinical examination by a suitably trained healthcare professional, carry out all of the following tests in babies with significant hyperbilirubinaemia as part of an assessment for underlying disease (see threshold table and the treatment threshold graphs from the CG98 full guideline): Serum bilirubin (for baseline level to assess response to treatment). Blood packed cell volume. Blood group (mother and baby). DAT. Interpret the result taking account of the strength of reaction, and whether mother received prophylactic anti-D immunoglobulin during pregnancy.When assessing the baby for underlying disease, consider whether the following tests are clinically indicated: full blood count and examination of blood film blood glucose-6-phosphate dehydrogenase levels, taking account of ethnic origin microbiological cultures of blood, urine and/or cerebrospinal fluid (if infection is suspected).SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG98", "drug": {}}}, {"category": "treatment", "id": "t299", "name": "treatment", "draggable": "true", "value": {"name": "treatment", "type": "treatment related", "time": "", "intention": "", "description": "title:treatment", "drug": {}}}, {"category": "drug", "id": "d410", "name": "albumin", "draggable": "true", "value": {"name": "albumin", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d118", "name": "calcium", "draggable": "true", "value": {"name": "calcium", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d333", "name": "hold", "draggable": "true", "value": {"name": "hold", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d169", "name": "clofibrate", "draggable": "true", "value": {"name": "clofibrate", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d149", "name": "charcoal", "draggable": "true", "value": {"name": "charcoal", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d324", "name": "glycerin", "draggable": "true", "value": {"name": "glycerin", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d155", "name": "cholestyramine", "draggable": "true", "value": {"name": "cholestyramine", "time": "None", "period": "None", "dosage": "None"}}]}